We are live on ! Find out more

Anavex Life Sciences

AVXL

Market cap $120M

1.29 USD

-0.02

1.53%

At close Updated Oct 28, 1:43 PM EDT

1 day

-1.53%

5 days

-3.01%

1 month

-45.11%

3 months

-49.81%

6 months

-61.72%

Year to date

-64.95%

1 year

-84.07%

5 years

-92.88%

10 years

-56.42%

About: Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Employees: 34

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - October 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period").

Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL) on November 30, 2026

New York, New York--(Newsfile Corp. - October 28, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL) on November 30, 2026

AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses

ROSEN, A LONGSTANDING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines – AVXL

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines – AVXL

ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

New York, New York--(Newsfile Corp. - October 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Anavex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Anavex Life Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm

What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

Complaint alleges Anavex Life Sciences Corp. misled investors between November 26, 2025 and August 28, 2026; investors may seek lead plaintiff role by November 30, 2026 LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026. The Anavex Life Sciences Corp. case, Kurey v.

What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

Kaplan Fox Reminds Investors of a Securities Class Action Against Anavex Life Sciences Corp. (AVXL) - Deadline is November 30, 2026

New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Reminds Investors of a Securities Class Action Against Anavex Life Sciences Corp. (AVXL) - Deadline is November 30, 2026

See News Rankings

Price charts implemented using Lightweight Charts™